Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for two Postdoctoral Fellows to join Memming Park’s group (funding from NIH R01 DA056404-04).

Offered conditions

- Competitive remuneration package commensurate with skills, qualifications and experience;
- Full immersion into a research excellence ecosystem with highly motivated researchers, supported by state-of-the-art technology and continuous development opportunities.

Organised by Broadreach Global with the European Brain Foundation (EBC), this summit will  bring together - in a collaborative, roundtable format - a highly diverse group of key opinion leaders, from  innovators, to decision-makers. 

When it comes to sexual competition, males have the star role. Clashing bodies, locking horns, biting and kicking are all considered fair play. Since these behaviours are so salient and robust, most studies focus on male behaviour, leaving females aside. 
 

Two editions of the European Researchers’ Night will be held at the incredible premises of the Champalimaud Centre for the Unknown located in Lisbon.

To reach members of the public from underserved and underprivileged communities, the European Researchers’ Night will be supported by several pre-events and co-created by researchers and members of the public, namely students from the school programmes and artists.

Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for a postdoctoral researcher to join our team.

The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030. Surgery remains the most effective treatment, yet for 70-80% of patients, surgery is not a viable option. Understanding pancreatic cancer at the cellular and subcellular level is essential for developing therapies that can buy patients more time.